早期PET阴性的局限期霍奇金淋巴瘤患者接受ABVD联合或不联合放疗后的复发模式:EORTC/LYSA/FIL H10与NCRI RAPID试验的联合分析
在H10和RAPID随机试验中,早期PET阴性的局限期霍奇金淋巴瘤患者接受化疗联合放疗(CMT)对比单纯化疗(C)。H10试验中,CMT组复发率低于单纯化疗组,且复发多发生在2年内和原受累区域。联合分析显示,省略放疗导致更多早期复发,主要影响原受累区域;放疗显著降低了早期复发风险。
要点
- 早期PET阴性局限期霍奇金淋巴瘤省略放疗后早期复发增多,主要在原受累区域。
- H10试验中预后良好组CMT后复发2/227(1%),单纯化疗后30/238(13%)。
- 联合分层分析显示放疗显著降低早期复发风险。
核心结论
- 在早期PET阴性的局限期霍奇金淋巴瘤中,省略放疗导致更多早期复发,主要影响原受累区域;放疗显著降低了联合分层分析中的早期复发风险。
研究设计与样本
- 对H10和RAPID随机试验中早期PET阴性的局限期霍奇金淋巴瘤患者进行复发模式分析,H10试验纳入1059例早期PET阴性患者(465例预后良好,594例预后不良),RAPID试验纳入419例早期PET阴性患者(241例预后良好,128例预后不良,50例未分类),采用调整Cox模型研究放疗对复发风险的影响,并分析时间变化效应。
主要发现
- H10试验预后良好组:CMT后复发2/227(1%),单纯化疗后复发30/238(13%);单纯化疗后复发者中21/30(70%)发生在2年内,25/30(83%)累及原受累区域。
- H10试验预后不良组:CMT后复发16/292(5%),其中8/16(50%)发生在2年内,11/16(69%)累及原受累区域;单纯化疗后复发30/302(10%),其中27/30(90%)发生在2年内,26/30(87%)累及原受累区域。
- RAPID试验预后良好组:CMT后复发6/118(5%),单纯化疗后复发13/123(11%);单纯化疗后复发者中11/13(85%)发生在2年内,11/13(85%)累及原受累区域。
- RAPID试验预后不良组:CMT后复发3/65(5%),单纯化疗后复发5/63(8%)。
- 在两项试验中,早期PET阴性霍奇金淋巴瘤省略放疗导致更多早期复发,主要影响原受累区域;联合分层分析显示放疗显著降低早期复发风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In the H10 and RAPID randomised trials, chemotherapy+radiotherapy (combined modalities treatment, CMT) was compared with chemotherapy (C) in limited-stage Hodgkin lymphoma (HL), with negative early positron emission tomography (ePETneg). We analysed patterns of relapses in the H10 trial, validated findings in the RAPID trial and performed a combined analysis stratified by trial. The impact of radiotherapy (RT) on risk of relapse was studied using adjusted Cox models, with time-varying effects. In H10, 1,059 ePETneg patients were included (465 European Organisation for Research and Treatment of Cancer (EORTC) favourable [F], 594 unfavourable [U]). Among the F patients, 2/227 (1%) relapsed after CMT, 30/238 (13%) after C: of these relapses, 21/30 (70%) occurred in less than 2 years and 25/30 (83%) affected originally involved areas. Among the U group, 16/292 (5%) relapsed after CMT: 8/16 (50%) in less than 2 years, 11/16 (69%) in originally involved areas. After C 30/302 (10%) relapsed: 27/30 (90%) in less than 2 years, and 26/30 (87%) in originally involved areas. Similar results were observed in 419 ePETneg RAPID patients (241 F, 128 U, 50 unclassified): among F patients, 6/118 (5%) relapsed after CMT; 13/123 (11%) after C: 11/13 (85%) in less than 2 years and 11/13 (85%) affecting originally involved areas. In U patients, 3/65 (5%) relapsed after CMT and 5/63 (8%) after C. In both trials, omitting RT in ePETneg HL resulted in more early relapses, mainly affecting originally involved areas. RT significantly reduced risk of early relapses in the combined stratified analysis.
引用
- Fiaccadori V, Neven A, Fortpied C, et al. Relapse patterns in early-PET negative, limited-stage Hodgkin lymphoma (HL) after ABVD with or without radiotherapy-a joint analysis of EORTC/LYSA/FIL H10 and NCRI RAPID trials. Br J Haematol. 2022. PMID: 36541117. doi:10.1111/bjh.18594
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。